Cullinan Oncology Key Executives
This section highlights Cullinan Oncology's key executives, including their titles and compensation details.
Find Contacts at Cullinan Oncology
(Showing 0 of )
Cullinan Oncology Earnings
This section highlights Cullinan Oncology's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.
Next Earnings Date
Last Earnings Results
Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|
Cullinan Oncology Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with non-small cell lung cancer. Its preclinical products include CLN-049, a humanized bispecific antibody for the treatment of acute myeloid leukemia; CLN-619, a monoclonal antibody for the treatment of solid tumors; CLN-617, a fusion protein for the treatment of solid tumors; CLN-978, a T cell engaging antibody for B-cell malignancies; Opal, a bispecific fusion protein to block the PD-1 axis, and to activate the 4-IBB/CD137 pathway on T cells in tumors; and Jade, a cell therapy to target a novel senescence and cancer-related protein. The company has collaboration agreements with Cullinan Pearl Corp. to develop, manufacture, and commercialize CLN-081 and products containing CLN-081; and Adimab, LLC to discover and/or optimize antibodies. Cullinan Oncology, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
$8.29
Stock Price
$485.07M
Market Cap
111
Employees
Cambridge, MA
Location
Financial Statements
Access annual & quarterly financial statements for Cullinan Oncology, including income statements, balance sheets, and cash flow statements..
Annual Income Statement
| Breakdown | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 | December 31, 2019 |
|---|---|---|---|---|---|
| Revenue | $- | $- | $18.94M | $- | $- |
| Cost of Revenue | $310.00K | $93.00K | $53.00K | $62.00K | $70.00K |
| Gross Profit | $-310.00K | $-93.00K | $18.89M | $-62.00K | $-70.00K |
| Gross Profit Ratio | 0.00% | 0.00% | 99.70% | 0.00% | 0.00% |
| Research and Development Expenses | $148.16M | $91.95M | $57.75M | $43.21M | $16.79M |
| General and Administrative Expenses | $42.49M | $40.19M | $29.15M | $17.12M | $5.48M |
| Selling and Marketing Expenses | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $42.49M | $40.19M | $29.15M | $17.12M | $5.48M |
| Other Expenses | $440.00K | $57.00K | $-8.00K | $-11.00K | $-4.00K |
| Operating Expenses | $191.09M | $132.14M | $86.90M | $60.34M | $22.27M |
| Cost and Expenses | $191.09M | $132.14M | $86.90M | $60.34M | $22.27M |
| Interest Income | $21.63M | $6.61M | $477.00K | $888.00K | $620.00K |
| Interest Expense | $- | $- | $- | $- | $- |
| Depreciation and Amortization | $310.00K | $93.00K | $53.00K | $62.00K | $70.00K |
| EBITDA | $-190.34M | $151.41M | $-67.90M | $-60.27M | $-22.20M |
| EBITDA Ratio | 0.00% | 0.00% | -358.73% | 0.00% | 0.00% |
| Operating Income | $-191.09M | $144.65M | $-67.95M | $-60.34M | $-22.27M |
| Operating Income Ratio | 0.00% | 0.00% | -358.73% | 0.00% | 0.00% |
| Total Other Income Expenses Net | $21.87M | $6.67M | $469.00K | $877.00K | $616.00K |
| Income Before Tax | $-169.22M | $151.32M | $-67.48M | $-59.46M | $-21.65M |
| Income Before Tax Ratio | 0.00% | 0.00% | -356.25% | 0.00% | 0.00% |
| Income Tax Expense | $-14.12M | $42.12M | $-2.44M | $-8.61M | $-1.62M |
| Net Income | $-153.16M | $111.21M | $-65.04M | $-50.85M | $-20.04M |
| Net Income Ratio | 0.00% | 0.00% | -343.35% | 0.00% | 0.00% |
| EPS | $-3.69 | $2.46 | $-1.47 | $-1.17 | $-0.46 |
| EPS Diluted | $-3.69 | $2.38 | $-1.47 | $-1.17 | $-0.46 |
| Weighted Average Shares Outstanding | 41.51M | 45.16M | 44.29M | 43.52M | 43.52M |
| Weighted Average Shares Outstanding Diluted | 41.55M | 46.64M | 44.29M | 43.52M | 43.52M |
| SEC Filing | Source | Source | Source | Source | Source |
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $-37.85M | $- | $- | $18.94M | $- | $- | $- | $- |
| Cost of Revenue | $- | $- | $77.00K | $76.00K | $77.00K | $80.00K | $81.00K | $72.00K | $59.00K | $9.00K | $- | $- | $12.00K | $13.00K | $13.00K | $- | $- | $- | $- | $- |
| Gross Profit | $- | $- | $-77.00K | $-76.00K | $-77.00K | $-80.00K | $-81.00K | $-72.00K | $-59.00K | $-9.00K | $- | $- | $-37.86M | $-13.00K | $-13.00K | $18.94M | $- | $- | $- | $- |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 100.00% | 0.00% | 0.00% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research and Development Expenses | $40.49M | $35.51M | $36.26M | $30.65M | $34.85M | $33.82M | $27.39M | $52.10M | $21.32M | $19.68M | $26.41M | $24.54M | $20.88M | $12.68M | $11.78M | $12.41M | $16.63M | $9.91M | $12.50M | $4.17M |
| General and Administrative Expenses | $14.56M | $13.35M | $13.77M | $12.34M | $10.64M | $10.98M | $10.21M | $10.66M | $11.29M | $10.09M | $10.70M | $8.12M | $13.47M | $5.70M | $4.83M | $5.16M | $12.54M | $1.59M | $1.63M | $1.37M |
| Selling and Marketing Expenses | $- | $- | $-77.00K | $-76.00K | $-77.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $14.56M | $13.35M | $13.69M | $12.27M | $10.56M | $10.98M | $10.21M | $10.66M | $11.29M | $10.09M | $10.70M | $8.12M | $13.47M | $5.70M | $4.83M | $5.16M | $12.54M | $1.59M | $1.63M | $1.37M |
| Other Expenses | $- | $- | $-72.00K | $-44.00K | $-117.00K | $180.00K | $69.00K | $107.00K | $298.00K | $- | $-241.00K | $- | $4.00K | $-2.00K | $-8.00K | $-2.00K | $-12.00K | $- | $1.00K | $- |
| Operating Expenses | $55.05M | $48.85M | $49.95M | $42.91M | $45.41M | $44.80M | $37.60M | $62.76M | $32.61M | $29.77M | $37.11M | $32.66M | $34.35M | $18.38M | $16.60M | $17.57M | $29.17M | $11.50M | $14.12M | $5.54M |
| Cost and Expenses | $55.05M | $48.85M | $50.03M | $42.99M | $45.48M | $44.80M | $37.60M | $62.76M | $32.61M | $29.77M | $37.11M | $32.66M | $34.35M | $18.38M | $16.60M | $17.57M | $29.17M | $11.50M | $14.12M | $5.54M |
| Interest Income | $7.51M | $8.38M | $8.07M | $5.69M | $5.92M | $5.88M | $5.32M | $4.51M | $3.36M | $2.35M | $697.00K | $197.00K | $137.00K | $118.00K | $173.00K | $49.00K | $79.00K | $185.00K | $246.00K | $378.00K |
| Interest Expense | $- | $- | $- | $- | $- | $- | $- | $- | $- | $2.35M | $697.00K | $197.00K | $- | $- | $- | $- | $- | $- | $- | $- |
| Depreciation and Amortization | $77.00K | $76.00K | $77.00K | $76.00K | $77.00K | $80.00K | $81.00K | $72.00K | $59.00K | $9.00K | $12.00K | $13.00K | $12.00K | $13.00K | $13.00K | $15.00K | $15.00K | $15.00K | $16.00K | $16.00K |
| EBITDA | $-54.97M | $-48.78M | $-49.95M | $-42.91M | $-45.41M | $-44.72M | $-37.52M | $-62.68M | $-34.55M | $-29.76M | $-35.39M | $-32.64M | $-34.34M | $-18.36M | $-16.59M | $1.39M | $-29.09M | $-11.48M | $-13.86M | $-5.53M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 90.75% | 0.00% | 0.00% | 7.24% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | $-55.05M | $-48.85M | $-50.03M | $-42.99M | $-45.48M | $-45.24M | $-37.60M | $-62.76M | $-32.61M | $-29.77M | $239.68M | $-32.66M | $-34.35M | $-18.38M | $-16.60M | $1.37M | $-29.17M | $-11.50M | $-14.12M | $-5.54M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 90.75% | 0.00% | 0.00% | 7.24% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income Expenses Net | $7.52M | $8.29M | $8.00M | $5.65M | $5.80M | $6.06M | $5.39M | $4.62M | $3.66M | $2.35M | $456.00K | $197.00K | $141.00K | $116.00K | $165.00K | $47.00K | $67.00K | $185.00K | $247.00K | $378.00K |
| Income Before Tax | $-47.53M | $-40.56M | $-42.03M | $-37.34M | $-39.69M | $-39.18M | $-32.21M | $-58.14M | $-28.95M | $-27.41M | $240.13M | $-32.46M | $-34.20M | $-18.26M | $-16.44M | $1.42M | $-29.11M | $-11.31M | $-13.88M | $-5.16M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 90.37% | 0.00% | 0.00% | 7.49% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | $117.00K | $- | $- | $-192.00K | $-14.12M | $-5.44M | $-5.40M | $-179.00K | $-1.86M | $-2.52M | $66.07M | $-19.57M | $223.00K | $-1.03M | $-976.00K | $1.43M | $6.90M | $-1.46M | $-5.50M | $-190.00K |
| Net Income | $-47.65M | $-40.56M | $-42.03M | $-37.15M | $-23.80M | $-39.18M | $-32.21M | $-57.96M | $-27.09M | $-24.89M | $174.90M | $-12.89M | $-32.51M | $-17.35M | $-15.64M | $-70.00K | $-28.35M | $-9.86M | $-8.62M | $-4.97M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 85.90% | 0.00% | 0.00% | -0.37% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | $-0.81 | $-0.70 | $-0.76 | $-0.86 | $-0.56 | $-0.92 | $-0.81 | $-1.42 | $-0.59 | $-0.55 | $3.90 | $-0.29 | $-0.76 | $-0.40 | $-0.36 | $0.00 | $-0.68 | $-0.26 | $-0.45 | $-0.26 |
| EPS Diluted | $-0.81 | $-0.70 | $-0.76 | $-0.86 | $-0.56 | $-0.92 | $-0.81 | $-1.42 | $-0.59 | $-0.55 | $3.77 | $-0.29 | $-0.74 | $-0.40 | $-0.36 | $0.00 | $-0.68 | $-0.26 | $-0.45 | $-0.26 |
| Weighted Average Shares Outstanding | 58.58M | 58.34M | 55.05M | 43.01M | 42.79M | 42.73M | 39.95M | 40.68M | 45.75M | 45.61M | 44.87M | 44.43M | 42.55M | 43.44M | 43.30M | 41.98M | 41.40M | 37.83M | 19.36M | 19.36M |
| Weighted Average Shares Outstanding Diluted | 58.58M | 58.34M | 55.05M | 43.01M | 42.79M | 42.73M | 39.95M | 40.68M | 45.75M | 45.61M | 46.38M | 44.43M | 43.64M | 43.44M | 43.30M | 41.98M | 41.98M | 37.83M | 19.36M | 19.36M |
| SEC Filing | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source |
Annual Balance Sheet
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Cash and Cash Equivalents | $83.00M | $98.43M | $550.12M | $430.86M | $168.20M |
| Short Term Investments | $315.97M | $368.63M | $311.14M | $230.69M | $42.01M |
| Cash and Short Term Investments | $398.98M | $467.07M | $550.12M | $430.86M | $210.21M |
| Net Receivables | $- | $- | $- | $- | $- |
| Inventory | $- | $- | $- | $- | $- |
| Other Current Assets | $15.69M | $13.12M | $7.18M | $12.20M | $4.14M |
| Total Current Assets | $414.67M | $480.19M | $474.47M | $296.56M | $212.28M |
| Property Plant Equipment Net | $2.35M | $3.53M | $5.30M | $77.00K | $130.00K |
| Goodwill | $- | $- | $- | $- | $- |
| Intangible Assets | $- | $- | $- | $- | $- |
| Goodwill and Intangible Assets | $- | $- | $- | $- | $- |
| Long Term Investments | $204.44M | $- | $80.88M | $140.40M | $- |
| Tax Assets | $- | $- | $- | $- | $- |
| Other Non-Current Assets | $366.00K | $459.00K | $459.00K | $147.00K | $2.30M |
| Total Non-Current Assets | $207.16M | $3.99M | $86.64M | $140.62M | $2.43M |
| Other Assets | $- | $- | $- | $- | $- |
| Total Assets | $621.82M | $484.18M | $561.12M | $437.19M | $214.71M |
| Account Payables | $1.68M | $2.49M | $2.66M | $3.17M | $9.68M |
| Short Term Debt | $1.30M | $1.44M | $1.60M | $- | $- |
| Tax Payables | $- | $- | $4.28M | $- | $- |
| Deferred Revenue | $- | $- | $- | $- | $- |
| Other Current Liabilities | $27.66M | $24.20M | $13.96M | $8.58M | $4.64M |
| Total Current Liabilities | $30.65M | $28.14M | $22.50M | $11.75M | $14.32M |
| Long Term Debt | $849.00K | $2.15M | $3.59M | $- | $- |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $- | $- | $- | $65.00K | $74.00K |
| Total Non-Current Liabilities | $849.00K | $2.15M | $3.59M | $65.00K | $276.73M |
| Other Liabilities | $- | $- | $- | $- | $- |
| Total Liabilities | $31.50M | $30.29M | $26.09M | $11.81M | $291.05M |
| Preferred Stock | $- | $- | $- | $- | $276.65M |
| Common Stock | $6.00K | $4.00K | $5.00K | $4.00K | $1.00K |
| Retained Earnings | $-368.24M | $-200.86M | $-47.70M | $-158.91M | $-93.34M |
| Accumulated Other Comprehensive Income Loss | $-133.00K | $-129.00K | $-2.60M | $-838.00K | $-2.00K |
| Other Total Stockholders Equity | $958.70M | $654.68M | $585.32M | $584.71M | $15.70M |
| Total Stockholders Equity | $590.33M | $453.70M | $535.03M | $422.58M | $-77.64M |
| Total Equity | $590.33M | $453.89M | $535.03M | $422.98M | $-76.34M |
| Total Liabilities and Stockholders Equity | $621.82M | $484.18M | $561.12M | $434.79M | $214.71M |
| Minority Interest | $- | $192.00K | $- | $403.00K | $1.30M |
| Total Liabilities and Total Equity | $621.82M | $484.18M | $561.12M | $434.79M | $214.71M |
| Total Investments | $520.41M | $368.63M | $392.02M | $371.09M | $42.01M |
| Total Debt | $2.15M | $3.59M | $5.19M | $- | $- |
| Net Debt | $-80.85M | $-94.84M | $-544.93M | $-430.86M | $-168.20M |
Balance Sheet Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and Cash Equivalents | $83.00M | $102.08M | $115.02M | $74.23M | $98.43M | $64.85M | $512.12M | $122.13M | $550.12M | $242.66M | $353.56M | $76.12M | $430.86M | $88.11M | $123.67M | $293.54M | $168.20M | $166.00M | $51.10M | $-98.63M |
| Short Term Investments | $315.97M | $475.99M | $547.47M | $358.78M | $368.63M | $401.58M | $349.96M | $268.57M | $311.14M | $333.29M | $257.43M | $238.74M | $230.69M | $232.94M | $213.03M | $147.34M | $42.01M | $53.59M | $51.87M | $197.26M |
| Cash and Short Term Investments | $398.98M | $578.08M | $662.50M | $433.01M | $467.07M | $466.43M | $512.12M | $390.70M | $550.12M | $575.95M | $611.00M | $314.85M | $430.86M | $321.04M | $336.70M | $440.87M | $210.21M | $219.59M | $102.97M | $98.63M |
| Net Receivables | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Inventory | $- | $- | $- | $- | $-5.40M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Current Assets | $15.69M | $13.96M | $15.30M | $12.71M | $13.12M | $10.28M | $6.44M | $8.33M | $7.18M | $12.25M | $23.69M | $7.46M | $12.20M | $15.59M | $15.52M | $12.84M | $4.14M | $2.14M | $1.69M | $- |
| Total Current Assets | $414.67M | $592.04M | $677.80M | $445.72M | $480.19M | $476.71M | $512.12M | $399.03M | $474.47M | $582.08M | $622.84M | $322.31M | $296.56M | $328.84M | $344.47M | $447.29M | $212.28M | $221.73M | $104.66M | $98.63M |
| Property Plant Equipment Net | $2.35M | $2.78M | $2.96M | $3.25M | $3.53M | $3.99M | $4.66M | $5.06M | $5.30M | $5.29M | $1.13M | $1.26M | $77.00K | $89.00K | $102.00K | $115.00K | $130.00K | $146.00K | $157.00K | $- |
| Goodwill | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Intangible Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Goodwill and Intangible Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Long Term Investments | $204.44M | $57.98M | $- | $- | $- | $13.54M | $18.63M | $110.44M | $80.88M | $29.41M | $43.18M | $94.18M | $140.40M | $124.33M | $119.64M | $32.11M | $- | $- | $- | $- |
| Tax Assets | $- | $- | $- | $- | $914.00K | $- | $- | $- | $- | $- | $- | $19.57M | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Assets | $366.00K | $460.00K | $460.00K | $460.00K | $459.00K | $459.00K | $-13.42M | $459.00K | $459.00K | $460.00K | $100.00K | $147.00K | $147.00K | $147.00K | $147.00K | $147.00K | $2.30M | $141.00K | $141.00K | $-98.63M |
| Total Non-Current Assets | $207.16M | $61.22M | $3.42M | $3.71M | $4.91M | $18.00M | $9.87M | $115.96M | $86.64M | $35.16M | $44.41M | $115.15M | $140.62M | $124.57M | $119.89M | $32.37M | $2.43M | $287.00K | $298.00K | $-98.63M |
| Other Assets | $- | $- | $- | $- | $-0 | $- | $- | $- | $- | $0 | $- | $- | $- | $- | $- | $- | $- | $0 | $- | $- |
| Total Assets | $621.82M | $653.25M | $681.22M | $449.43M | $485.10M | $494.71M | $521.98M | $514.99M | $561.12M | $617.24M | $667.25M | $437.46M | $437.19M | $453.40M | $464.35M | $479.67M | $214.71M | $222.02M | $104.96M | $- |
| Account Payables | $1.68M | $2.12M | $1.55M | $3.71M | $2.49M | $951.00K | $2.49M | $2.03M | $2.66M | $1.52M | $3.10M | $6.31M | $3.17M | $2.02M | $1.51M | $3.88M | $9.68M | $3.49M | $4.46M | $- |
| Short Term Debt | $1.30M | $1.26M | $2.43M | $1.33M | $2.88M | $3.47M | $3.54M | $3.40M | $1.60M | $1.39M | $1.07M | $1.32M | $- | $- | $- | $- | $- | $- | $- | $- |
| Tax Payables | $- | $- | $- | $- | $- | $- | $- | $4.21M | $4.28M | $11.40M | $46.50M | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Revenue | $- | $- | $- | $- | $- | $17.45M | $12.62M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Current Liabilities | $27.66M | $20.83M | $19.49M | $16.89M | $22.76M | $19.02M | $13.65M | $16.53M | $13.96M | $12.81M | $11.37M | $9.63M | $8.58M | $5.84M | $4.23M | $6.01M | $4.64M | $4.25M | $1.50M | $- |
| Total Current Liabilities | $30.65M | $24.20M | $23.48M | $21.93M | $28.14M | $23.44M | $19.68M | $26.17M | $22.50M | $27.12M | $62.03M | $17.26M | $11.75M | $7.86M | $5.74M | $9.89M | $14.32M | $7.73M | $5.97M | $- |
| Long Term Debt | $849.00K | $1.19M | $1.52M | $1.84M | $2.15M | $2.45M | $2.73M | $3.17M | $3.59M | $3.99M | $596.00K | $736.00K | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $914.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $65.00K | $67.00K | $70.00K | $73.00K | $74.00K | $74.00K | $- | $- |
| Total Non-Current Liabilities | $849.00K | $1.19M | $1.52M | $1.84M | $3.06M | $2.45M | $2.73M | $3.17M | $3.59M | $3.99M | $596.00K | $736.00K | $65.00K | $67.00K | $70.00K | $73.00K | $276.73M | $74.00K | $- | $- |
| Other Liabilities | $- | $- | $- | $1 | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities | $31.50M | $25.39M | $25.00M | $23.77M | $31.20M | $25.89M | $22.41M | $29.34M | $26.09M | $31.11M | $62.63M | $17.99M | $11.81M | $7.93M | $5.81M | $9.97M | $291.05M | $7.81M | $5.97M | $- |
| Preferred Stock | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $151.81M | $151.81M | $137.77M |
| Common Stock | $6.00K | $6.00K | $6.00K | $4.00K | $4.00K | $4.00K | $4.00K | $4.00K | $5.00K | $5.00K | $5.00K | $4.00K | $4.00K | $4.00K | $4.00K | $4.00K | $1.00K | $3.00K | $- | $- |
| Retained Earnings | $-368.24M | $-320.59M | $-280.03M | $-238.00M | $-200.86M | $-177.05M | $-137.87M | $-105.66M | $-47.70M | $-20.91M | $3.89M | $-171.01M | $-158.91M | $-126.39M | $-109.05M | $-93.41M | $-93.34M | $-64.99M | $-55.13M | $- |
| Accumulated Other Comprehensive Income Loss | $-133.00K | $970.00K | $-476.00K | $-331.00K | $-129.00K | $-1.05M | $-1.62M | $-1.24M | $-2.60M | $-3.93M | $-3.63M | $-3.13M | $-838.00K | $-58.00K | $-115.00K | $-60.00K | $-2.00K | $59.00K | $204.00K | $-40.77M |
| Other Total Stockholders Equity | $958.70M | $947.48M | $936.72M | $664.00M | $654.68M | $646.92M | $639.07M | $592.54M | $585.32M | $610.97M | $604.27M | $592.84M | $584.71M | $569.84M | $564.71M | $560.37M | $292.35M | $2.63M | $945.00K | $864.00K |
| Total Stockholders Equity | $590.33M | $627.86M | $656.22M | $425.67M | $453.70M | $468.82M | $499.57M | $485.65M | $535.03M | $586.13M | $604.54M | $418.70M | $422.58M | $443.39M | $455.55M | $466.90M | $-77.64M | $212.35M | $97.83M | $97.86M |
| Total Equity | $590.33M | $627.86M | $656.22M | $425.67M | $453.89M | $468.82M | $499.57M | $485.65M | $535.03M | $586.13M | $604.62M | $419.47M | $422.98M | $445.47M | $458.54M | $469.70M | $-76.34M | $214.21M | $98.92M | $97.86M |
| Total Liabilities and Stockholders Equity | $621.82M | $653.25M | $681.22M | $449.43M | $485.10M | $494.71M | $521.98M | $514.99M | $561.12M | $617.24M | $667.25M | $437.46M | $434.79M | $453.40M | $464.35M | $479.67M | $214.71M | $222.02M | $104.89M | $97.86M |
| Minority Interest | $- | $- | $- | $- | $192.00K | $- | $- | $- | $- | $- | $80.00K | $768.00K | $403.00K | $2.09M | $2.99M | $2.80M | $1.30M | $1.86M | $1.09M | $- |
| Total Liabilities and Total Equity | $621.82M | $653.25M | $681.22M | $449.43M | $485.10M | $494.71M | $521.98M | $514.99M | $561.12M | $617.24M | $667.25M | $437.46M | $434.79M | $453.40M | $464.35M | $479.67M | $214.71M | $222.02M | $104.89M | $97.86M |
| Total Investments | $520.41M | $533.97M | $547.47M | $358.78M | $368.63M | $415.13M | $368.60M | $379.01M | $392.02M | $362.71M | $300.61M | $332.91M | $461.38M | $357.27M | $332.67M | $179.45M | $42.01M | $53.59M | $51.87M | $197.26M |
| Total Debt | $2.15M | $2.45M | $2.73M | $3.17M | $3.59M | $5.92M | $6.27M | $6.57M | $5.19M | $4.69M | $1.13M | $2.06M | $- | $- | $- | $- | $- | $- | $- | $- |
| Net Debt | $-80.85M | $-99.64M | $-112.29M | $-71.06M | $-94.84M | $-58.93M | $-505.85M | $-115.56M | $-544.93M | $-237.97M | $-352.43M | $-74.06M | $-430.86M | $-88.11M | $-123.67M | $-293.54M | $-168.20M | $-166.00M | $-51.10M | $98.63M |
Annual Cash Flow
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Net Income | $-167.57M | $-153.16M | $109.19M | $-67.48M | $-59.46M |
| Depreciation and Amortization | $306.00K | $310.00K | $93.00K | $53.00K | $62.00K |
| Deferred Income Tax | $- | $- | $- | $3.10M | $233.00K |
| Stock Based Compensation | $37.82M | $30.44M | $27.96M | $24.38M | $14.91M |
| Change in Working Capital | $-389.00K | $-339.00K | $11.18M | $-3.54M | $6.85M |
| Accounts Receivables | $- | $- | $- | $- | $- |
| Inventory | $- | $- | $- | $- | $- |
| Accounts Payables | $-812.00K | $-167.00K | $-509.00K | $-4.83M | $5.58M |
| Other Working Capital | $423.00K | $-172.00K | $11.69M | $1.29M | $1.27M |
| Other Non Cash Items | $-15.47M | $-11.52M | $-275.08M | $67.00K | $7.63M |
| Net Cash Provided by Operating Activities | $-145.30M | $-134.28M | $-126.66M | $-43.43M | $-29.77M |
| Investments in Property Plant and Equipment | $- | $-208.00K | $-1.13M | $-589.23K | $-10.00K |
| Acquisitions Net | $- | $-36.01K | $275.00M | $923.00K | $1.45M |
| Purchases of Investments | $-721.13M | $-373.38M | $-377.92M | $-525.81M | $-69.76M |
| Sales Maturities of Investments | $584.82M | $409.40M | $352.93M | $192.04M | $62.90M |
| Other Investing Activities | $- | $36.01K | $91.00K | $-333.77K | $-5.41K |
| Net Cash Used for Investing Activities | $-136.31M | $35.81M | $248.97M | $-333.77M | $-5.42M |
| Debt Repayment | $- | $1.82M | $-2.20M | $- | $- |
| Common Stock Issued | $262.65M | $38.39M | $6.02K | $267.27M | $145.45M |
| Common Stock Repurchased | $- | $- | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- |
| Other Financing Activities | $3.54M | $538.00K | $-23.73M | $1.52M | $138.88M |
| Net Cash Used Provided by Financing Activities | $266.19M | $40.75M | $-25.93M | $268.78M | $140.14M |
| Effect of Forex Changes on Cash | $- | $- | $- | $- | $- |
| Net Change in Cash | $-15.43M | $-57.72M | $96.38M | $-108.42M | $104.95M |
| Cash at End of Period | $83.00M | $98.43M | $156.15M | $59.77M | $168.20M |
| Cash at Beginning of Period | $98.43M | $156.15M | $59.77M | $168.20M | $63.25M |
| Operating Cash Flow | $-145.30M | $-134.28M | $-126.66M | $-43.43M | $-29.77M |
| Capital Expenditure | $- | $-208.00K | $-1.13M | $-589.23K | $-10.00K |
| Free Cash Flow | $-145.30M | $-134.48M | $-127.80M | $-44.02M | $-29.78M |
Cash Flow Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $-47.65M | $-40.56M | $-42.03M | $-37.15M | $-23.80M | $-39.18M | $-32.21M | $-58.14M | $-27.09M | $-24.89M | $174.06M | $-12.89M | $-34.21M | $-18.26M | $-16.44M | $1.42M | $-29.11M | $-11.31M | $-13.88M | $-5.16M |
| Depreciation and Amortization | $77.00K | $76.00K | $77.00K | $76.00K | $77.00K | $80.00K | $81.00K | $72.00K | $59.00K | $9.00K | $12.00K | $13.00K | $12.00K | $13.00K | $13.00K | $15.00K | $15.00K | $15.00K | $16.00K | $16.00K |
| Deferred Income Tax | $- | $- | $- | $- | $-6.13M | $607.00K | $1.10M | $- | $19.57M | $- | $- | $-19.57M | $67.19M | $909.00K | $803.00K | $-1.49M | $87.00K | $- | $- | $- |
| Stock Based Compensation | $9.63M | $9.43M | $10.53M | $8.23M | $7.52M | $7.74M | $7.92M | $7.26M | $7.51M | $5.27M | $8.61M | $6.57M | $12.14M | $4.56M | $4.17M | $3.51M | $14.91M | $- | $- | $- |
| Change in Working Capital | $4.82M | $1.84M | $-1.15M | $-5.90M | $3.31M | $-181.00K | $-4.65M | $1.18M | $-5.01M | $-34.91M | $48.07M | $3.03M | $5.75M | $2.21M | $-4.82M | $-6.69M | $4.49M | $1.32M | $933.00K | $107.00K |
| Accounts Receivables | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Inventory | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Accounts Payables | $-434.00K | $560.00K | $-2.15M | $1.21M | $1.54M | $-1.54M | $461.00K | $-630.00K | $1.15M | $-1.58M | $-3.21M | $3.14M | $1.15M | $515.00K | $-2.37M | $-4.12M | $4.52M | $-976.00K | $1.87M | $170.00K |
| Other Working Capital | $5.25M | $1.28M | $1.00M | $-7.12M | $1.77M | $1.36M | $-5.11M | $630.00K | $-6.16M | $-33.33M | $51.28M | $-109.00K | $4.61M | $1.70M | $-2.45M | $-2.56M | $-23.00K | $2.29M | $-937.00K | $-63.00K |
| Other Non Cash Items | $-3.51M | $-4.93M | $9.11M | $3.67M | $897.00K | $-3.20M | $-3.25M | $-1.37M | $-20.02M | $171.00K | $-256.18M | $946.00K | $-66.07M | $17.00K | $82.00K | $1.72M | $164.00K | $911.00K | $6.68M | $25.00K |
| Net Cash Provided by Operating Activities | $-36.63M | $-34.14M | $-36.29M | $-38.25M | $-18.13M | $-34.14M | $-31.01M | $-51.00M | $-24.98M | $-54.35M | $-25.42M | $-21.91M | $-15.17M | $-10.55M | $-16.20M | $-1.51M | $-9.44M | $-9.07M | $-6.25M | $-5.01M |
| Investments in Property Plant and Equipment | $- | $- | $- | $- | $- | $- | $-49.00K | $-159.00K | $-882.00K | $-251.00K | $- | $- | $- | $- | $- | $- | $1.00K | $-4.00K | $-4.00K | $-3.00K |
| Acquisitions Net | $- | $- | $- | $- | $- | $- | $-12.16K | $-15.34K | $-5.00M | $5.00M | $- | $- | $- | $- | $923.00K | $- | $-1.45M | $- | $1.45M | $- |
| Purchases of Investments | $-168.04M | $-96.80M | $-324.93M | $-131.37M | $-66.01M | $-136.78M | $-81.45M | $-89.14M | $-160.42M | $-124.13M | $-36.35M | $-57.02M | $-77.26M | $-85.30M | $-213.49M | $-149.76M | $-21.50M | $-16.18M | $-1.00M | $-31.09M |
| Sales Maturities of Investments | $184.00M | $116.67M | $139.82M | $144.32M | $117.48M | $93.82M | $93.61M | $104.48M | $132.60M | $61.40M | $67.20M | $91.73M | $61.40M | $59.71M | $58.90M | $12.04M | $32.94M | $14.24M | $11.53M | $4.20M |
| Other Investing Activities | $- | $- | $-185.11M | $12.96M | $51.47K | $-42.96K | $12.16K | $15.34K | $5.09M | $5.00M | $270.00M | $34.71M | $-15.86M | $-25.59M | $-154.59M | $-137.73M | $12.89M | $-1.94M | $1.45M | $-26.89M |
| Net Cash Used for Investing Activities | $15.96M | $19.88M | $-185.11M | $12.96M | $51.47M | $-42.96M | $12.11M | $15.18M | $-28.61M | $-57.98M | $300.85M | $34.71M | $-15.86M | $-25.59M | $-154.59M | $-137.73M | $11.44M | $-1.94M | $11.97M | $-26.89M |
| Debt Repayment | $- | $- | $- | $- | $- | $- | $- | $1.82M | $-2.20M | $- | $- | $800.00K | $- | $- | $- | $- | $- | $- | $- | $- |
| Common Stock Issued | $- | $-4.42M | $265.99M | $1.08M | $248.00K | $290.00K | $38.39M | $-36.00K | $-4.39M | $1.43M | $4.40M | $- | $-267.27M | $579.00K | $- | $267.27M | $-14.25M | $- | $- | $14.25M |
| Common Stock Repurchased | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Financing Activities | $1.58M | $1.32M | $262.20M | $1.08M | $248.00K | $112.00K | $38.60M | $-36.00K | $-30.71M | $1.43M | $2.01M | $2.74M | $2.70M | $579.00K | $923.00K | $-2.69M | $124.90M | $1.21M | $- | $-213.00K |
| Net Cash Used Provided by Financing Activities | $1.58M | $1.32M | $262.20M | $1.08M | $248.00K | $112.00K | $38.60M | $1.79M | $-32.91M | $1.43M | $2.01M | $3.54M | $2.70M | $579.00K | $923.00K | $264.58M | $124.90M | $1.21M | $- | $14.04M |
| Effect of Forex Changes on Cash | $- | $- | $- | $- | $1 | $80.19M | $-16.46M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Net Change in Cash | $-19.08M | $-12.94M | $40.79M | $-24.21M | $33.59M | $-76.99M | $19.71M | $-34.02M | $-86.50M | $-110.91M | $277.44M | $16.34M | $-28.33M | $-35.56M | $-169.87M | $125.34M | $126.90M | $-9.81M | $5.72M | $-17.87M |
| Cash at End of Period | $83.00M | $102.08M | $115.02M | $74.23M | $98.43M | $64.85M | $141.83M | $122.13M | $156.15M | $242.66M | $353.56M | $76.12M | $59.77M | $88.11M | $123.67M | $293.54M | $168.20M | $41.30M | $51.10M | $45.38M |
| Cash at Beginning of Period | $102.08M | $115.02M | $74.23M | $98.43M | $64.85M | $141.83M | $122.13M | $156.15M | $242.66M | $353.56M | $76.12M | $59.77M | $88.11M | $123.67M | $293.54M | $168.20M | $41.30M | $51.10M | $45.38M | $63.25M |
| Operating Cash Flow | $-36.63M | $-34.14M | $-36.29M | $-38.25M | $-18.13M | $-34.14M | $-31.01M | $-51.00M | $-24.98M | $-54.35M | $-25.42M | $-21.91M | $-15.17M | $-10.55M | $-16.20M | $-1.51M | $-9.44M | $-9.07M | $-6.25M | $-5.01M |
| Capital Expenditure | $- | $- | $- | $- | $- | $- | $-49.00K | $-159.00K | $-882.00K | $-251.00K | $- | $- | $- | $- | $- | $- | $1.00K | $-4.00K | $-4.00K | $-3.00K |
| Free Cash Flow | $-36.63M | $-34.14M | $-36.29M | $-38.25M | $-18.13M | $-34.14M | $-31.05M | $-51.16M | $-25.86M | $-54.60M | $-25.42M | $-21.91M | $-15.17M | $-10.55M | $-16.20M | $-1.51M | $-9.44M | $-9.07M | $-6.25M | $-5.02M |
Cullinan Oncology Dividends
Explore Cullinan Oncology's dividend history, including dividend yield, payout ratio, and historical payments.
Cullinan Oncology News
Read the latest news about Cullinan Oncology, including recent articles, headlines, and updates.
Cullinan Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results
Initial clinical data from global Phase 1 study of CLN-978 in Systemic Lupus Erythematosus (SLE) expected in Q4 2025; CLN-978 remains the first and only development-stage CD19 T cell engager in an autoimmune disease clinical trial in the U.S. Zipalertinib pivotal Phase 2b study met primary endpoint; full results mid-year 2025 and NDA submission planned H2 2025, pending regulatory discussions Cash and investments of $606.9 million as of December 31, 2024, continues to provide runway into 2028 CAMBRIDGE, Mass., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “Cullinan”), a biopharmaceutical company focused on developing modality-agnostic targeted therapies, today reported recent and anticipated business highlights and announced its financial results for the fourth quarter and full year ended December 31, 2024.
Cullinan Therapeutics to Participate in Upcoming Investor Conferences
CAMBRIDGE, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “Cullinan”), a biopharmaceutical company focused on developing modality-agnostic targeted therapies, today announced its participation in the following upcoming investor conferences: Nadim Ahmed, Chief Executive Officer, and Jeffrey Jones, M.D.
Cullinan Therapeutics' CLN-978 And Zipalertinib Look Promising In NSCLC
Cullinan Therapeutics focuses on unaddressed or unmet needs in oncology and autoimmune conditions. In particular, Zipalertinib and CLN-978 stand out as its most promising product candidates. Zipalertinib targets a tiny niche in the large NSCLC market. Management expects to report its Phase 2b results by mid-2025. Similarly, CLN-978 is a first-in-class T-cell engager targeting SLE and RA. It can also potentially be expanded into other B-cell-mediated indications eventually.
Cullinan Therapeutics: Casting A Wide Net With Their Pipeline
Cullinan Therapeutics is a multifocal biotech with promising programs in precision medicine and immunotherapy, despite recent market sentiment declines. Zipalertinib shows potential in treating exon 20 insertion mutation-positive NSCLC, with a 40% objective response rate in early phase trials. CGEM has a strong financial position with cash reserves projected to fund operations into 2028, reducing the need for immediate equity raises.
Cullinan Therapeutics to Participate in Fireside Chat at Stifel 2024 Healthcare Conference
CAMBRIDGE, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “Cullinan”), a biopharmaceutical company focused on developing modality-agnostic targeted therapies, today announced that Nadim Ahmed, Chief Executive Officer, and Jeffrey Jones, M.D., M.B.A., Chief Medical Officer, will participate in a fireside chat at the Stifel 2024 Healthcare Conference, being held in New York on November 18 and 19, 2024.
Cullinan Therapeutics to Present Preclinical Data for CLN-978, a CD19-directed T Cell Engager, at ACR Convergence 2024
CAMBRIDGE, Mass., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on developing modality-agnostic targeted therapies, today announced the upcoming presentation of preclinical data for CLN-978, a novel CD19xCD3 bispecific T cell engager, at American College of Rheumatology (ACR) Convergence 2024, taking place in Washington, D.C. from November 14-19, 2024.
Cullinan Therapeutics Receives U.S. FDA Clearance of Investigational New Drug Application for CLN-978 Administered Subcutaneously in Patients with Moderate to Severe Systemic Lupus Erythematosus
CLN-978 is the first development stage CD19 T cell engager to receive U.S. FDA IND clearance in autoimmune diseases CAMBRIDGE, Mass., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on developing modality-agnostic targeted therapies, today announced that the U.S. Food and Drug Administration (FDA) cleared the Company's Investigational New Drug (IND) Application for CLN-978 and its global Phase 1 clinical trial may proceed in the U.S. to assess CLN-978 in patients with moderate to severe systemic lupus erythematosus (SLE).
Cullinan Therapeutics Receives Approval to Initiate its Global Phase 1 Clinical Trial of CLN-978 for the Treatment of Systemic Lupus Erythematosus
Phase 1 clinical trial is designed to assess the safety, pharmacokinetics and initial clinical activity of CLN-978 for patients with systemic lupus erythematosus
Cullinan Therapeutics Presents Positive Updated Data from Module C of Zipalertinib Pivotal Phase 2b Study at ESMO 2024
Updated data show consistent objective response rate of 40% and manageable safety profile in patients with non-small cell lung cancer harboring epidermal growth factor receptor exon 20 insertion mutations treated with zipalertinib who progressed on or after prior amivantamab treatment
Cullinan Therapeutics Announces Positive Initial Data from Pivotal Phase 2b REZILIENT1 Study of Zipalertinib
Objective response rate of 39% with manageable safety profile in patients with non-small cell lung cancer (NSCLC) harboring EGFR Exon 20 insertion mutations treated with zipalertinib who had progressed after prior amivantamab treatment Objective response rate of 39% with manageable safety profile in patients with non-small cell lung cancer (NSCLC) harboring EGFR Exon 20 insertion mutations treated with zipalertinib who had progressed after prior amivantamab treatment
Cullinan Therapeutics to Participate in Fireside Chat at TD Cowen 5th Annual Oncology Innovation Summit
CAMBRIDGE, Mass., May 24, 2024 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on developing modality-agnostic targeted therapies, today announced that Nadim Ahmed, Chief Executive Officer and Jeffrey Jones, MD, MBA, Chief Medical Officer, will participate in a fireside chat at the TD Cowen 5th Annual Oncology Innovation Summit: Insights for ASCO & EHA, being held virtually on May 28 and 29, 2024.
Cullinan Therapeutics to Present First Data for CLN-619, a Novel Anti-MICA/B Antibody, in Combination with a Checkpoint Inhibitor and Updated Monotherapy Data at ASCO 2024
Preliminary data from CLN-619 in combination with checkpoint inhibitor pembrolizumab show objective responses in patients with tumor types that are typically unresponsive to pembrolizumab, such as non-small cell lung cancer (NSCLC) with oncogenic mutations
Cullinan Therapeutics Announces Appointment of Mary Kay Fenton as Chief Financial Officer
CAMBRIDGE, Mass., April 29, 2024 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on modality-agnostic targeted therapies, today announced the appointment of Mary Kay Fenton as Chief Financial Officer, beginning April 29.
Cullinan Therapeutics to Present Clinical Data from Phase 1 Study Evaluating Novel Anti-MICA/B Antibody, CLN-619, as Monotherapy and in Combination with a Checkpoint Inhibitor in Patients with Advanced Solid Tumors at ASCO 2024
CAMBRIDGE, Mass., April 24, 2024 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on modality-agnostic targeted therapies, today announced that clinical data from its Phase 1 trial of CLN-619 in patients with advanced solid tumors will be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting taking place in Chicago from May 31-June 4, 2024. The data will include first results from the dose escalation cohort of CLN-619 in combination with checkpoint inhibitor pembrolizumab and updated results from the monotherapy dose escalation cohort in patients with advanced solid tumors.
Cullinan Therapeutics Announces Oversubscribed $280 million Private Placement
Financing includes new and existing leading life sciences institutional investors Proceeds, along with existing cash and cash equivalents, are expected to extend cash runway into 2028 Cullinan to host a virtual investor event on April 16 at 8:00 am ET CAMBRIDGE, Mass., April 16, 2024 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (formerly Cullinan Oncology, Inc.) (Nasdaq: CGEM; “Cullinan”), a biopharmaceutical company focused on developing modality-agnostic targeted therapies, today announced that it has entered into a stock purchase agreement with certain institutional and accredited investors for a private placement of approximately $274.0 million of shares of its common stock at a price of $19.00 per share and, in lieu of common stock to certain investors, $6.0 million of pre-funded warrants to purchase shares of its common stock at a price of $18.999 per pre-funded warrant.
Cullinan Oncology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results
Cullinan remains on track to report additional solid tumor dose escalation data for CLN-619 in the second quarter of 2024 and recently received FDA clearance for an IND to evaluate CLN-619 in relapsed/refractory multiple myeloma
Cullinan Oncology Announces U.S. FDA Clearance of Investigational New Drug Application for Novel MICA/B Antibody, CLN-619, for Relapsed/Refractory Multiple Myeloma
Company will initiate Phase 1 study of CLN-619 for relapsed or refractory multiple myeloma, first MICA/B antibody clinical study in hematologic malignancies
Cullinan Oncology to Participate in Upcoming Investor Conferences
CAMBRIDGE, Mass., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan Oncology”) a biopharmaceutical company focused on modality-agnostic targeted oncology therapies, today announced its participation in the following upcoming investor conferences:
Cullinan Oncology to Present at the 42nd Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass., Dec. 18, 2023 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan Oncology”) a biopharmaceutical company focused on modality-agnostic targeted oncology therapies, today announced that Chief Executive Officer, Nadim Ahmed, will present at the 42nd Annual J.P. Morgan Healthcare Conference, being held January 8-11, 2024 in San Francisco, CA. Mr. Ahmed's presentation is scheduled for Thursday, January 11, at 10:30 am PST (1:30 pm EST).
Cullinan Oncology Announces First Patient Dosed in Phase 1 Trial Evaluating CLN-617, a Novel Fusion Protein Uniquely Harnessing Both IL-2 and IL-12 Cytokines
CAMBRIDGE, Mass., Dec. 14, 2023 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on modality-agnostic, targeted oncology therapies, today announced that the first patient has been dosed with CLN-617 in a Phase 1 clinical trial. This is a first-in-human, multi-center, open label study designed to evaluate the safety, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of CLN-617 alone and in combination with pembrolizumab, a programmed death receptor-1 (PD-1) targeted checkpoint inhibitor, in patients with advanced solid tumors.
Cullinan Oncology to Present Data Demonstrating Progress Across Its Broad Immunotherapy-Pipeline at SITC 2023
Five abstracts accepted for poster presentation at the Society for Immunotherapy of Cancer 2023 Annual Meeting Preliminary clinical biomarker data for anti-MICA/B antibody, CLN-619, supports proposed mechanism of action and demonstrates that the observed monotherapy clinical activity was seen in patients with tumors not typically responsive to checkpoint inhibitor therapy Data highlight progress of Cullinan's diverse pipeline including CLN-619, an anti-MICA/B antibody; CLN-418, a B7H4X4-1BB-bispecific immune activator; CLN-978, a CD19XCD3 bispecific T cell engager; and CLN-617, a fusion protein harnessing IL-2 and IL-12 cytokines CAMBRIDGE, Mass., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (NASDAQ: CGEM) (“Cullinan”), a biopharmaceutical company focused on modality-agnostic targeted oncology therapies, today announced that it will present data across four distinct immuno-oncology programs in five poster presentations at the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting taking place November 1-5 in San Diego.
Cullinan Oncology: Inexplicably Trading Below Cash Despite Robust Data
Cullinan Oncology's stock remains below cash value despite positive phase 1 trial data for its second asset, CLN-619. The company's lead asset, Zipalertinib, has shown promising results in treating EGFRex20ins NSCLC, positioning it as a potential treatment of choice in this patient population. Cullinan Oncology has initiated a phase 3 study for Zipalertinib and has released encouraging data for its second candidate, CLN-619, in heavily pretreated patients.
Similar Companies
Related Metrics
Explore detailed financial metrics and analysis for CGEM.